|
Only HER2 Breast Cancer benefits from Adrymycian
Results from two studies presented Thursday at the 30th annual San Antonio Breast Cancer Symposium now reveal that only women with HER2 positive breast cancer -- a subset which accounts for only about 8 percent of women with breast cancer worldwide -- will benefit significantly from standard anthracycline-based chemotherapy.
Read entire article:
http://www.abcnews.go.com/Health/OnC...4001402&page=1
__________________
Kate
Stage IIIC Diagnosed Oct 25, 2005 (age 58)
ER/PR-, HER2+++, grade 3, Ploidy/DNA index: Aneuploid/1.61, S-phase: 24.2%
Neoadjunct chemo: 4 A/C; 4 Taxatore
Bilateral mastectomy June 8, 2006
14 of 26 nodes positive
Herceptin June 22, 2006 - April 20, 2007
Radiation (X35) July 24-September 11, 2006
BRCA1/BRCA2 negative
Stage IV lung mets July 13, 2007 - TCH
Single brain met - August 6, 2007 -CyberKnife
Oct 2007 - clear brain MRI and lung mets shrinking.
March 2008 lung met progression, brain still clear - begin Tykerb/Xeloda/Ixempra
|